PDF(Pubmed)
Abstract：
Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligible for surgery. Herein, we present a case of advanced ICC in which radical surgery was not possible due to tumor invasion of the second porta hepatis and right hepatic artery. Six treatment cycles with a gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion, as tumor invasion of the second porta hepatis and right hepatic artery was no longer evident. The patient subsequently underwent successful radical surgical resection, including hepatectomy, caudate lobe resection, and cholecystectomy combined with lymph node dissection. Cases of patients with advanced ICC undergoing surgical resection after combined immunotherapy and chemotherapy are rare. The GEMOX regimen combined with camrelizumab demonstrated favorable antitumor efficacy and safety, suggesting that it might be a potential feasible and safe conversion therapy strategy for patients with advanced ICC.
摘要：
肝内胆管细胞癌(ICC)是最常见的侵袭性恶性肿瘤之一,5年生存率低于5%。目前,根治性手术切除是ICC的首选治疗方法。然而,大多数患者仅在晚期诊断，因此不符合手术条件。在这里，我们介绍了一例晚期ICC，其中由于第二肝门和右肝动脉的肿瘤侵犯，无法进行根治性手术。吉西他滨和奥沙利铂（GEMOX）方案联合卡姆瑞珠单抗免疫治疗的六个治疗周期实现了部分反应和成功的肿瘤转化，由于第二肝门和右肝动脉的肿瘤侵袭不再明显。患者随后接受了成功的根治性手术切除，包括肝切除术,尾状叶切除,胆囊切除联合淋巴结清扫术。经联合免疫治疗和化疗后接受手术切除的晚期ICC患者很少见。GEMOX方案联合camrelizumab显示出良好的抗肿瘤疗效和安全性，提示对于晚期ICC患者可能是一种可行且安全的转换治疗策略.
